Cargando…

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617

Mostrar otras versiones (1)

In this study, it was aimed to investigate (149)Tb-PSMA-617 for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. (149)Tb-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-posit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Umbricht, Christoph A., Köster, Ulli, Bernhardt, Peter, Gracheva, Nadezda, Johnston, Karl, Schibli, Roger, van der Meulen, Nicholas P., Müller, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882876/ https://www.ncbi.nlm.nih.gov/pubmed/31780798 http://dx.doi.org/10.1038/s41598-019-54150-w

Ejemplares similares

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Preclinical investigations and first-in-human application of $^{152}$Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
por: Müller, Cristina, et al.
Publicado: (2016)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Terbium-149 for targeted alpha therapy
por: Borgna, Francesca, et al.
Publicado: (2021)

Preclinical in vivo application of $^{152}$Tb-DOTANOC: a radiolanthanide for PET imaging
por: Müller, Cristina, et al.
Publicado: (2016)

Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging
por: Müller, Cristina, et al.
Publicado: (2016)

Terbium-149 for targeted alpha therapy
por: Grundler, Pascal, et al.
Publicado: (2023)

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with $^152$Tb-DOTATOC
por: Baum, Richard P, et al.
Publicado: (2017)

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods
por: UYGUR, EMRE, et al.
Publicado: (2023)

(161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic
por: Favaretto, Chiara, et al.
Publicado: (2023)

Therapeutic Potential of (47)Sc in Comparison to (177)Lu and (90)Y: Preclinical Investigations
por: Siwowska, Klaudia, et al.
Publicado: (2019)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

A pilot study of (68) Ga-PSMA-617 PET/CT imaging and (177)Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
por: Wang, Guochang, et al.
Publicado: (2022)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

PSMA-617 inhibits proliferation and potentiates the (177)Lu-PSMA-617-induced death of human prostate cancer cells
por: Zhao, Yi, et al.
Publicado: (2023)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

Establishment of a clinical SPECT/CT protocol for imaging of (161)Tb
por: Marin, I., et al.
Publicado: (2020)

Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
por: Tschan, Viviane J., et al.
Publicado: (2022)

Preclinical Assessment Addressing Intravenous Administration of a [(68)Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution
por: Mandiwana, Vusani, et al.
Publicado: (2021)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

(64)Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model
por: Han, Xue-Di, et al.
Publicado: (2017)

Results from extended lymphadenectomies with [(111)In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
por: Jilg, Cordula A., et al.
Publicado: (2020)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
por: Verburg, Frederik A., et al.
Publicado: (2023)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

Preclinical evaluation of [(58m)Co]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer
por: Baun, Christina, et al.
Publicado: (2023)

(68)Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617
por: de Vries, Lisa H., et al.
Publicado: (2020)

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute
por: Müller, Cristina, et al.
Publicado: (2019)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v41nklbsp78sstof5pkt6n19tj